How your 10 most-tipped ASX growth stocks performed in 2025

2025 has proven to be a great year for growth stocks on the whole, with AI, and tech more broadly, driving a lot of the returns seen on global equities markets.

After shrugging off tariff-related worries following Trump's Liberation Day shock in April, global stock markets surged to new highs despite concerns over stretched valuations and growing talks of bubbles. 

But has it been the same story on the ASX, and in particular the growth stocks picked out by our readers? 

Around a year ago, we asked our Livewire and Market Index readers for their top ASX growth stocks picks for 2025 as part of our 2025 Outlook Series Survey. Almost 5,000 of you took part. As we count down to the end of the year, it's time to revisit the picks and see how you got on. 

Please note: We are sharing information from the Livewire and Market Index readerships by publishing this list. We hope it inspires ideas for your investment research. This information is not, nor is it intended to be, a set of recommendations. Please do your own research and seek advice from a professional. Past performance is not a reliable indicator of future return. 

Your 10 most-tipped ASX growth stocks for 2025

As you can see from the list above, your top 10 ended up featuring a few familiar names and a lot of recent market darlings, with an interesting mix of large- and mid-caps. 

While tech featured prominently (Life360, Wisetech Global, Technology One and Catapult Group), it was actually biotech that proved most popular, with CSL, Pro Medicus and Telix Pharmaceuticals receiving the most votes. 

Three resources stocks - BHP Group, Woodside Energy and Mineral Resources - rounded out the top 10.

So how did they do?

The results

Key metrics

• Highest total return: Life360 (54.92%), Mineral Resources (50.83%), BHP Group (20.20%)
• Lowest total return: Telix Pharmaceuticals (-44.33%), WiseTech Global (-41.09%), CSL Limited (-34.89%)
• Average total return: 1.65% (non-weighted)
• ASX 200 total return: 8.46% 
• Highest dividend yield: Woodside (9.67%), BHP (6.17%), CSL (1.61%)
• Most popular sectors: Tech (4), Healthcare (3), Resources (3)
• Number of stocks with a positive return: 5 (50%)
• Average positive return: +30.70%
• Number of stocks with a negative return: 5 (50%)
• Average negative return: -27.41%

CSL endures a horrid year

Despite once again topping the list as your most-tipped growth stock (as it has for the last decade or so), CSL (ASX: CSL) ends the year as arguably the ASX's most notable underperformer. 

The big turning point came in August, when CSL's FY25 results sent investors running for the exits. Despite reporting sales growth of 5% and NPAT growth of 17% - to US$3 billion - soft guidance, huge job cuts and the planned demerger of its vaccine arm Sequirus saw CSL shares plummet 16% in a day. 

To compound the misery, at the company's AGM on 28 October, CEO Paul McKenzie announced CSL was slashing its guidance for FY26 and beyond.

As a result, CSL shares dropped another 16% in a day.

It meant the CSL share price had fallen from $271 pre-earnings to as low as $170 by late October - a sad state of affairs for one of the ASX's enduring growth darlings.

Health scare for Healthcare

CSL wasn't the only ASX Healthcare name to sell off in 2025. The sector closes out the year 22.5% down, the worst-performing of all sectors on the ASX, and one of only two in the red year-to-date. 

Unfortunately, the two other Healthcare stocks that made your most-tipped list in 2025 didn't buck that trend. 

Telix Pharmaceuticals (ASX: TLX) took the crown as the worst overall performer on the list, finishing the year down 44%.

No stranger to volatility (TLX saw a 53% drawdown in 2022 and a 26% fall in 2023), the diagnostic radiopharmaceuticals company started the year on the crest of a wave, having surged from less than $4 a share in 2022 to $24.

But a series of regulatory setbacks in July and August and a series of class-action lawsuits in November saw it give up most of its gains since 2023. 

By contrast, Pro Medicus (ASX: PME) ended the year effectively where it started. Another ASX darling, PME sold off hard off the back of positive earnings leading into Liberation Day before climbing to a new all-time high by July. 

It has since retraced to $233, leaving it down 6.5% for the year, even if it remains an ASX growth story worth paying attention to.

Tech an extremely mixed bag

Despite being arguably the dominant market narrative of 2025, ASX tech was more hit-and-miss this year after a late rotation away from the sector poured cold water on many stocks that had been running hot or were mounting a recovery. 

We can start with the winners. 

Life360 (ASX: 360) has been one of the ASX's undisputed growth success stories this year. It is now up 54.9%, and at one point was up 245% before the recent market rotation out of tech stocks. 

It has built on impressive revenue numbers in 2025 and shown growth in the US, even as MAU missed expectations in the September quarter.

 

Sports data analytics company Catapult (ASX: CAT) was a similar story. It ends the year 17% up, despite at one point having returned more than 100% in the year to September. The acquisition of German firm Impect in October, funded by a $130m institutional placement, stoked dilution concerns, even if it remains on track to deliver 20% CAGR to FY28. 

Now to the losers.

Technology One (ASX: TNE) is down 10.19% overall in 2025, despite showing strength mid-year. Despite FY25 results showing the company increased revenue 18% YoY, TNE shed its gains for the year as part of the wider tech sector selloff and disappointments over annual recurring revenue growth (ARR) and FY26 guidance. 

Logistics software company WiseTech (ASX: WTC) experienced a rollercoaster in 2025, ultimately ending the year down 41%.

It started 2025 near record highs but lost 20% in February after four board directors resigned as part of an ongoing disagreement surrounding the scandal-hit founder Richard White. 

Then came a mid-year recovery. But even strong FY results weren't enough to save it from a further selloff as soft guidance and rotation out of the sector saw it drop as low as $62 a share. 

MinRes delivers in strong year for Resources

One of the ASX's successful growth stories for 2025 could be found in the Resources sector. 

The biggest comeback story was undoubtedly Mineral Resources (ASX: MIN), which turned around a year-to-date drawdown of -59% and is on track to close out 2025 up around 50%.

This was despite posting a $904m loss in FY25 and enduring ongoing governance scandals surrounding founder and managing director Chris Ellison.

Recovering lithium prices, stable iron ore prices, the completion of its Onslow project and the recent above-consensus sale of some of its lithium business have been key positives.

Have your say for 2026

The 2026 Outlook Series is now open. By participating in the survey, you’ll help us to shape our coverage in 2026 to meet your investing needs. All survey participants will receive early access to 40 big investing ideas for 2026, including:

• Ten fundies’ #1 growth stock picks
• Livewire readers’ 10 most-tipped growth stocks, income picks and ETFs

You might also be one of three lucky people to score a $250 gift card!

TAKE PART HERE